HTF Market Intelligence released a new research report of 161 pages on title ‘Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market’ with detailed analysis, forecast and strategies.
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 – a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.
The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.
In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.
Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the first- and second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita – EGFR inhibitors that targeted towards EGFR T790M – are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.
There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS – abemaciclib – is being developed in the pipeline.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=323069
The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.
– How will immunotherapies such as atezolizumab contribute to growth?
– What effect will patent expirations of currently branded therapies have on market value?
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
– What are the common targets and mechanisms of action of pipeline therapies?
– Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
– What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
– How have the late-stage therapies performed in clinical trials?
– How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
– How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
– How could changes in risk factors such as population age, smoking habits and pollution influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
– How do deal frequency and value compare between target families and molecule types?
– What were the terms and conditions of key licensing deals?
Reasons to buy
This report will allow you to –
– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
– Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
– Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
– Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
– Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
– Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/323069-non-small-cell-lung-cancer-therapeutics-in-asia-pacific-market-1
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 12
2.3 Symptoms 13
2.4 Etiology and Pathophysiology 14
2.4.1 Adenocarcinoma 15
2.4.2 Squamous-Cell Carcinoma 18
2.4.3 Large-Cell Carcinoma 20
2.4.4 Immunotherapy 21
2.5 Diagnosis 21
2.6 Prognosis 24
2.7 Treatment Guidelines and Options 24
2.7.1 Treatment Algorithm 25
2.7.2 First-Line Treatment 26
2.7.3 Maintenance Therapy 28
2.7.4 Second-Line Treatment 29
2.7.5 Third-Line Therapy 30
2.7.6 Adjuvant Therapy 30
3 Marketed Products 31
3.1 Overview 31
3.2 Chemotherapies 31
3.2.1 Alimta (pemetrexed) – Eli Lilly 31
3.2.2 Abraxane (paclitaxel) – Celgene 32
3.3 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 33
3.3.1 Tarceva (erlotinib) – Roche 33
3.3.2 Iressa (gefitinib) – AstraZeneca 34
3.3.3 Gilotrif/Giotrif/Xovoltib (afatinib) – Boehringer Ingelheim 35
3.3.4 Tagrisso (osimertinib/AZD-9291) – AstraZeneca 36
3.3.5 Olita (olmutinib) – Hanmi Pharmaceuticals 37
3.3.6 Conmana (icotinib) – Betta Pharmaceuticals 38
3.4 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors 39
3.4.1 Xalkori (crizotinib) – Pfizer 39
3.4.2 Alecensa (alectinib) – Roche 39
3.4.3 Zykadia (ceritinib/LDK378) – Novartis 40
3.5 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors 41
3.5.1 Opdivo (nivolumab) – Bristol-Myers Squibb 41
3.5.2 Keytruda (pembrolizumab) – Merck & Co 42
3.6 Other 43
3.6.1 Avastin (bevacizumab) – Roche 43
3.6.2 Cyramza (Ramucirumab) – Eli Lilly 44
3.6.3 Ofev/Vargatef (Nintedanib) – Boehringer Ingelheim 44
3.7 Conclusion 45
3.8 Comparative Efficacy and Safety of Marketed Products 46
4 Pipeline Analysis 50
4.1 Overview 50
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 51
4.3 Pipeline by Molecular Target 53
4.4 Promising Pipeline Candidates 55
4.4.1 Yervoy (Ipilimumab) – Bristol-Myers Squibb 55
4.4.2 Tecentriq (Atezolizumab) – Roche 57
4.4.3 Necitumumab – Eli Lilly 59
4.4.4 Durvalumab plus Tremelimumab (MEDI-4736/MEDI-1123) – MedImmune 60
4.4.5 Veliparib – AbbVie 62
4.4.6 Vaxira – Recombio 63
4.4.7 Abemaciclib – Eli Lilly 64
4.4.8 Dacomitinib – Pfizer 65
4.4.9 Ensartinib (X-396) – Xcovery 67
4.4.10 Anlotinib (AL-3818) – Jiangsu Chia-Tai Tianqing 68
4.4.11 CimaVax-EGF (BVNSCLC-001) – Bioven 69
4.4.12 Brigatinib (AP-26113) – Ariad Pharmaceuticals 69
4.4.13 Naquotinib Mesylate (ASP8273) – Astellas Pharma 70
4.4.14 Plinabulin – BeyondSpring Pharma 71
4.4.15 Fruquintinib (HMPL-013) – Hutchison MediPharma 72
4.4.16 Famitinib (SHR-1020) – Jiangsu Hengrui Medicine 72
4.4.17 Vandetanib (ZD 6474) – Genzyme 73
4.4.18 Aitan (Apatinib) – Jiangsu Hengrui Medicine 73
4.5 Comparative Efficacy and Safety of Pipeline Products 74
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/323069-non-small-cell-lung-cancer-therapeutics-in-asia-pacific-market-1
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218